Supply Chain Intelligence

Matinas BioPharma Holdings, Inc. Supply Chain

MTNB supply chain intelligence for Matinas BioPharma Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MTNB ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
22Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Matinas BioPharma Holdings, Inc. (MTNB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

31Total relationships
2Distinct source URLs
6High confidence
0.725Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Matinas BioPharma Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
RUTGERS-UNIVERSITY RUTGERS-UNIVERSITY 92% we acquired a license from Rutgers University ("Rutgers") for certain patents related to the LNC Platform
BNTX BioNTech SE 72% contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations; ● expenses incurred under agreements with contract research org…
BNTX BioNTech SE 72% Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regu…
ORANY ORANY 72% produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue to explore relationships with well-respected third-party contract manufacturers fo…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: produce the clinical supplies of …

Matinas BioPharma Holdings, Inc. Customers

TickerNameConfidenceEvidence
X-GEN-PHARMACEUTICALS-INC X-GEN-PHARMACEUTICALS-INC 85% s), Rezzayo (rezafungin, marketed byCorMedix Therapeutics), Brexafemme (Ibrexafungerp marketed by GlaxoSmithKline) and amphotericin B deoxycholate (marketed by X-Gen Pharmaceuticals, Inc.). There cur…
BNTX BioNTech SE 72% Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from BNTX g…
BNTX BioNTech SE 72% . The lease impairment charges were included in the impairment charges of other assets line in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2024. Th…
DRTS Alpha Tau Medical Ltd. 72% Reciprocal relationship from DRTS graph: Reciprocal relationship from MTNB graph: Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnol…
DRTS Alpha Tau Medical Ltd. 72% Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004-2008). Ea…
LSTA Lisata Therapeutics, Inc. 72% elopment, business management and knowledge of the pharmaceutical, health care and securities industries. Robin L. Smith, MD, MBA. Dr. Smith has served on the Board since February 2025. Dr. Smith has…
LSTA Lisata Therapeutics, Inc. 72% Reciprocal relationship from LSTA graph: Reciprocal relationship from MTNB graph: elopment, business management and knowledge of the pharmaceutical, health care and securities industries. Robin L. Sm…
ORANY ORANY 72% produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue to explore relationships with well-respected third-party contract manufacturers fo…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from ORAN…
VIVS VivoSim Labs, Inc. 72% Reciprocal relationship from VIVS graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from MTNB graph: Vice President, Head of Global Lega…
VIVS VivoSim Labs, Inc. 72% Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004-2008). Ea…
ZCAR Zoomcar Holdings, Inc. 72% Reciprocal relationship from ZCAR graph: Reciprocal relationship from MTNB graph: Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnol…
ZCAR Zoomcar Holdings, Inc. 72% Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004-2008). Ea…
AQUARIUS-BIOTECHNOLOGIES-INC AQUARIUS-BIOTECHNOLOGIES-INC 62% medicinal products for human use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of…
BRM-HOLDINGS BRM-HOLDINGS 62% elopment, business management and knowledge of the pharmaceutical, health care and securities industries. Robin L. Smith, MD, MBA. Dr. Smith has served on the Board since February 2025. Dr. Smith has…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% d December 31, 2024, as required by Section 704 of the NYSE American Company Guide. We received a letter from the NYSE American on June 23, 2025 that we had resolved the deficiency set forth in the J…
F2G-LTD F2G-LTD 62% ct candidates that we are aware of in clinical development by third parties, such olorofim (being developed by F2G, Ltd), fosmanogepix (being developed by Basilea), and EL219, a derivative of amphote…
MATINAS-BIOPHARMA-INC MATINAS-BIOPHARMA-INC 62% medicinal products for human use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of…
MATINAS-BIOPHARMA-NANOTECHNOLOGIES-INC MATINAS-BIOPHARMA-NANOTECHNOLOGIES-INC 62% medicinal products for human use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of…
NEREUS-BIOPHARMA-LLC NEREUS-BIOPHARMA-LLC 62% medicinal products for human use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of…
NYSE-AMERICAN-COMPANY NYSE-AMERICAN-COMPANY 62% d December 31, 2024, as required by Section 704 of the NYSE American Company Guide. We received a letter from the NYSE American on June 23, 2025 that we had resolved the deficiency set forth in the J…
WESTERN-ACQUISITION-VENTURES-CORP WESTERN-ACQUISITION-VENTURES-CORP 62% elopment, business management and knowledge of the pharmaceutical, health care and securities industries. Robin L. Smith, MD, MBA. Dr. Smith has served on the Board since February 2025. Dr. Smith has…

Matinas BioPharma Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MTNB-DEBT-11121 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.
MTNB-DEBT Debt stack $1.4M 90% Market cache reports total debt of $1.4M.
MTNB-DEBT-11120 Warrants outstanding: 238000 90% xbrl warrant detail from xbrl 2025-12-31.

Matinas BioPharma Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Matinas BioPharma Holdings, Inc..

Matinas BioPharma Holdings, Inc. Ownership

HolderNameConfidenceEvidence
MTNB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 28 tracked holders.

Matinas BioPharma Holdings, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
AZN AstraZeneca PLC 100.00 2
BNTX BioNTech SE 100.00 1 ['customer', 'supplier']
TLX Telix Pharmaceuticals Limited 100.00 2
BSX Boston Scientific Corporation 100.00 2
ATNM Actinium Pharmaceuticals, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
CATX Perspective Therapeutics, Inc. 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
NBTX Nanobiotix S.A. 100.00 2
LLY Eli Lilly and Company 100.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
CBIO Crescent Biopharma, Inc. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
BLTE Belite Bio, Inc 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Matinas BioPharma Holdings, Inc..

Unlock full MTNB data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
MTNB
Unlock MTNB Supply Chain Data
Verified relationships include:
RUTGERS-UNIVERSITYRUTGERS-UNIVERSITYSupplier92%
BNTXBioNTech SESupplier72%
X-GEN-PHARMACEUTICALS-INCX-GEN-PHARMACEUTICALS-INCCustomer85%
BNTXBioNTech SECustomer72%
+27 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →